A 38-year-old woman presents to the emergency department in Delhi during the monsoon season with a 3-day history of sudden-onset fever (39.5°C), severe myalgia, headache, and dry cough. She reports that her 12-year-old son had similar symptoms 5 days ago. On examination, she appears acutely ill with conjunctival injection but no rash. Chest auscultation reveals bilateral fine crackles. A rapid antigen detection test (RADT) for influenza A is positive. Which of the following is the most appropriate immediate management?

Explanation

## Diagnosis & Clinical Context **Key Point:** This patient presents with classic influenza A presentation: acute fever, myalgia, headache, and respiratory symptoms in a household cluster during respiratory season. The positive RADT confirms influenza A. ## Antiviral Management in Influenza | Antiviral | Class | Dosing | Timing | Efficacy | Notes | |-----------|-------|--------|--------|----------|-------| | **Oseltamivir** | Neuraminidase inhibitor | 75 mg PO BD × 5 days | ≤48 hrs onset | Reduces duration by 1 day, ↓ complications | **First-line** | | Zanamivir | Neuraminidase inhibitor | 5 mg inhaled BD × 5 days | ≤48 hrs onset | Similar to oseltamivir | Risk of bronchospasm in asthma/COPD | | Amantadine | M2 channel blocker | 100 mg PO BD × 7 days | ≤48 hrs onset | Poor efficacy; **high resistance** | Outdated; not recommended | | Peramivir | Neuraminidase inhibitor | Single IV dose | Any time | For severe/hospitalized | Not first-line | **High-Yield:** Oseltamivir is the **gold standard** for treatment of uncomplicated influenza A in adults. Benefit is greatest when started within 48 hours of symptom onset. **Clinical Pearl:** This patient is at day 3 of illness—still within the 48-hour window for antiviral efficacy. Early treatment reduces symptom duration by ~1 day and prevents progression to severe pneumonia and secondary bacterial infection. ## Why Oseltamivir (Option 0) is Correct 1. **Neuraminidase inhibitor** — blocks viral release from infected cells; standard of care for influenza A and B. 2. **Timing:** Within 48 hours of symptom onset — critical for efficacy. 3. **Dosing:** 75 mg PO twice daily for 5 days is the standard adult regimen. 4. **Evidence:** Reduces symptom duration, hospitalizations, and secondary complications in non-severe influenza. 5. **Safety in pregnancy/reproductive age:** Oseltamivir is **safe** and even recommended in pregnant women; no teratogenicity. ## Why Each Distractor Is Wrong **Amantadine (Option 1):** - M2 channel blocker with **high rates of resistance** (>90% in many regions including India). - Inferior efficacy compared to neuraminidase inhibitors. - Outdated; not recommended by WHO or CDC for influenza A treatment. - Causes CNS side effects (tremor, insomnia, dizziness). **Supportive care alone (Option 2):** - **Misconception:** Antivirals are NOT contraindicated in women of reproductive age; oseltamivir is pregnancy category C and safe. - Antivirals reduce symptom duration and prevent complications—withholding them denies patient benefit. - This patient is still within 48-hour window; antiviral therapy is indicated. **Zanamivir (Option 3):** - While zanamivir is a valid neuraminidase inhibitor, it is **second-line** to oseltamivir. - **Contraindication:** Inhaled zanamivir carries risk of bronchospasm and is avoided in patients with underlying airway disease. - This patient has bilateral crackles (possible early pneumonia); inhaled route is suboptimal. - Oseltamivir (oral) is preferred for systemic delivery and safety.